Benchling, a San Francisco, CA-based life sciences R&D platform, raised $34.5m in Series C funding.
The round was led by Menlo Ventures with participation from new investors Lead Edge Capital and Y Combinator Continuity as well as returning investors Benchmark and Thrive Capital.
The company will use the funds to grow globally, extend its product lead and expand commercial relationships.
Led by Sajith Wickramasekara, CEO, Benchling provides a cloud-based R&D biotech platform for scientists to design DNA, collaborate on experiments, manage research workflows and make critical R&D decisions.
The solution, which features Notebook, Molecular Biology, Registry, Inventory, and Request & Workflow Management tools, is used by over 170,000 scientists globally across multinational pharmaceutical corporations, emerging biotechnology companies, and major research institutions. Customers include renowned academic labs at Harvard, MIT, Stanford, and Berkeley, Zoetis, Beam Therapeutics, Zymergen and Regeneron Pharmaceuticals.